Scaling Liquid Biopsies and Cancer Diagnostics: The E.A.S.Y. Way

Are siloed approaches to cancer detection becoming obsolete? Care convergence—the breaking down of barriers between medical disciplines—is emerging as the cornerstone of modern healthcare, with liquid biopsies at its leading edge.

In her recent Forbes article, Mariya Filipova highlights how non-invasive tests analyze bodily fluids for tumor-derived genetic material, enabling cross-specialty collaboration that views patients holistically rather than through fragmented specialty lenses.The potential market impact is substantial, with liquid biopsy growth projected to reach nearly $30 billion by 2032. While blood-based tests currently dominate the market (72% in 2023), Filipova identifies saliva-based screening for head and neck cancers as the next frontier. Using her E.A.S.Y. criteria framework—Efficiency, Accuracy, Scale, and Yield—she predicts multiple viable solutions will emerge within 24 months, fundamentally transforming how these often late-diagnosed cancers are detected.

Beyond financial projections, the true impact lies in the shift toward preventive, patient-centric care. As liquid biopsies move from specialized cancer centers into point-of-care settings like dental offices and primary care practices, they enable real-time cancer screening during routine visits. This convergence of diagnostics and treatment across disciplines doesn’t just improve early detection—it represents a paradigm shift toward treating cancer as the systemic disease it is, potentially saving countless lives through earlier intervention.

Mariya Filipova is a Managing Director of 4100DX and co-host of the Think Oral Health podcast. A seasoned Fortune 20 executive and systemic health investor, she specializes in scaling category-defining solutions in integrated care delivery and new payment models.